Details

Autor(en) / Beteiligte

• Tolaney, Sara M
• Barry, William T
• Dang, Chau T
• Yardley, Denise A
• Moy, Beverly
• Marcom, P. Kelly
• Albain, Kathy S
• Rugo, Hope S
• Ellis, Matthew
• Shapira, Iuliana
• Wolff, Antonio C
• Carey, Lisa A
• Overmoyer, Beth A
• Partridge, Ann H
• Guo, Hao
• Hudis, Clifford A
• Krop, Ian E
• Burstein, Harold J
• Winer, Eric P

Titel

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Ist Teil von

• The New England journal of medicine, 2015-01, Vol.372 (2), p.134-141

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• A multicenter single-group trial suggests that adjuvant therapy with paclitaxel plus trastuzumab lowers the risk of relapse in women with small HER2-positive breast cancers. Overexpression of the human epidermal growth factor receptor type 2 (HER2) occurs in approximately 15 to 20% of invasive breast cancers and was historically associated with poor clinical outcomes. 1 – 4 Trastuzumab, a humanized monoclonal antibody that binds HER2, improves the outcomes for patients with HER2-positive breast cancer. Four phase 3 randomized trials involving more than 8000 patients showed that when trastuzumab was administered in combination with or after chemotherapy, the risk of recurrence was decreased by approximately 50% and overall survival improved. 5 – 9 These trials focused largely on patients with stage II or stage III HER2-positive breast cancers. Although patients . . .